Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NELIA ESTHER SANCHEZ-CRESPO

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1790990851
CMS profile
699626
Location
HOLLYWOOD, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$728.73

30 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $728.73 30

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 1; records 1–30 of 30 matching records. This page contains 30 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NELIA ESTHER SANCHEZ-CRESPO

NPI 1790990851 · CMS profile ID 699626

Allopathic & Osteopathic Physicians / Internal Medicine

HOLLYWOOD, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–30 of 30 matching records. This page contains 30 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1790990851?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NELIA ESTHER SANCHEZ-CRESPO, NPI 1790990851, CMS profile ID 699626. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–30 of 30 matching records. This page contains 30 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790990851?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). NELIA ESTHER SANCHEZ-CRESPO, NPI 1790990851, CMS profile ID 699626. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–30 of 30 matching records. This page contains 30 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790990851?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
NELIA ESTHER SANCHEZ-CRESPO, NPI 1790990851, CMS profile ID 699626, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–30 of 30 matching records. This page contains 30 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1790990851?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

30 matching records · $728.73 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 30 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–30 of 30.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Astellas Pharma US Inc $34.4812/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238629709 CMS
Eisai Inc. $16.9112/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244502406 CMS
Bayer Healthcare Pharmaceuticals Inc. $22.7612/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225766734 CMS
Astellas Pharma US Inc $19.3611/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238580027 CMS
Kowa Pharmaceuticals America, Inc. $14.0411/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243117688 CMS
AstraZeneca Pharmaceuticals LP $22.9011/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206469581 CMS
AstraZeneca Pharmaceuticals LP $23.3010/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207078553 CMS
Exact Sciences Corporation $17.4210/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235577946 CMS
ViiV Healthcare Company $32.9409/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189597428 CMS
PFIZER INC. $18.2509/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229170669 CMS
Bayer Healthcare Pharmaceuticals Inc. $20.6908/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225766731 CMS
Exact Sciences Corporation $17.9608/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235577942 CMS
Novo Nordisk Inc $23.8308/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188341897 CMS
PFIZER INC. $21.6308/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229261293 CMS
AstraZeneca Pharmaceuticals LP $22.5708/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207251793 CMS
Novo Nordisk Inc $20.7007/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188313908 CMS
Lilly USA, LLC $18.5706/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186840529 CMS
Medtronic, Inc. $65.0505/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219054936 CMS
AstraZeneca Pharmaceuticals LP $19.2905/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207076131 CMS
AstraZeneca Pharmaceuticals LP $23.3004/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206804026 CMS
Lilly USA, LLC $29.1704/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186816693 CMS
Hologic Sales and Service, LLC $32.4903/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1182593795 CMS
Hologic Sales and Service, LLC $37.2403/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1182593779 CMS
Novo Nordisk Inc $17.0703/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188825717 CMS
ViiV Healthcare Company $22.2503/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189604703 CMS
Bayer Healthcare Pharmaceuticals Inc. $21.8202/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225766727 CMS
Exact Sciences Corporation $24.4402/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235577937 CMS
AstraZeneca Pharmaceuticals LP $22.1802/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207171245 CMS
Bayer Healthcare Pharmaceuticals Inc. $18.3301/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225766723 CMS
Exact Sciences Corporation $27.7901/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235577933 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $519.24 8
PY2020 $173.44 11
PY2021 $252.44 16
PY2022 $281.68 15
PY2023 $2,585.02 22
PY2024 $2,063.21 35
PY2025 $728.73 30

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $5,652,523.02 227
PY2024 Principal investigator $7,882,760.60 649
PY2023 Principal investigator $10,990,435.50 4,306
PY2022 Principal investigator $2,420,977.88 1,673
PY2021 Principal investigator $723,239.31 8
PY2020 Principal investigator $1,155,430.22 12

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

1,673 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125287
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125289
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125339
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125341
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125343
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125345
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125347
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125349
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125351
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125353
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125355
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125357
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125359
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125361
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125363
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125365
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125367
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15,531.55 12/21/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125327
Principal investigator 1 ModernaTX, Inc. $1,800.00 12/21/2022 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, Randomized, Stratified, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1073 (SARS-CoV-2 and Influenza Vaccine) Compared to Co-administered mRNA-1010 (Influenza) and mRNA-1273 (SARS-CoV-2) Vaccines and to mRNA- 1010 Vaccine and mRNA-1273 Vaccine Alone in Healthy Adults 18-75 Years of Age No dispute reported 06/30/2026 963252639
Principal investigator 1 Alnylam Pharmaceuticals Inc. $18.90 12/20/2022 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910125291
Principal investigator 1 Alnylam Pharmaceuticals Inc. $210.00 12/20/2022 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910125293
Principal investigator 1 Alnylam Pharmaceuticals Inc. $264.00 12/20/2022 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910125295
Principal investigator 1 Alnylam Pharmaceuticals Inc. $198.00 12/20/2022 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910125297
Principal investigator 1 Alnylam Pharmaceuticals Inc. $176.00 12/20/2022 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910125299
Principal investigator 1 Alnylam Pharmaceuticals Inc. $88.00 12/20/2022 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910125301
Principal investigator 1 Alnylam Pharmaceuticals Inc. $198.00 12/20/2022 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910125369
Principal investigator 1 ModernaTX, Inc. $1,841.38 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483243
Principal investigator 1 ModernaTX, Inc. $3,223.23 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483249
Principal investigator 1 ModernaTX, Inc. $2,020.46 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483253
Principal investigator 1 ModernaTX, Inc. $377.91 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483259
Principal investigator 1 ModernaTX, Inc. $377.91 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483265
Principal investigator 1 ModernaTX, Inc. $2,230.41 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483269
Principal investigator 1 ModernaTX, Inc. $2,230.41 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483275
Principal investigator 1 ModernaTX, Inc. $2,230.41 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483279
Principal investigator 1 ModernaTX, Inc. $2,230.41 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483285
Principal investigator 1 ModernaTX, Inc. $2,230.41 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483289
Principal investigator 1 ModernaTX, Inc. $1,841.38 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483295
Principal investigator 1 ModernaTX, Inc. $2,230.41 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483299
Principal investigator 1 ModernaTX, Inc. $1,841.38 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483305
Principal investigator 1 ModernaTX, Inc. $2,230.41 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483309
Principal investigator 1 ModernaTX, Inc. $2,230.41 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483315
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483319
Principal investigator 1 ModernaTX, Inc. $3,223.23 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483323
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483329
Principal investigator 1 ModernaTX, Inc. $2,230.41 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483333
Principal investigator 1 ModernaTX, Inc. $1,841.38 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483337
Principal investigator 1 ModernaTX, Inc. $2,020.46 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483343
Principal investigator 1 ModernaTX, Inc. $322.34 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483347
Principal investigator 1 ModernaTX, Inc. $1,125.08 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483353
Principal investigator 1 ModernaTX, Inc. $1,841.38 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483357
Principal investigator 1 ModernaTX, Inc. $2,329.83 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483361
Principal investigator 1 ModernaTX, Inc. $1,841.38 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483367
Principal investigator 1 ModernaTX, Inc. $1,853.74 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483373
Principal investigator 1 ModernaTX, Inc. $1,125.08 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483379
Principal investigator 1 ModernaTX, Inc. $1,841.38 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483383
Principal investigator 1 ModernaTX, Inc. $1,853.74 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483389
Principal investigator 1 ModernaTX, Inc. $1,841.38 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483393
Principal investigator 1 ModernaTX, Inc. $519.94 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483399
Principal investigator 1 ModernaTX, Inc. $2,230.41 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483403
Principal investigator 1 ModernaTX, Inc. $322.34 12/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483409
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482625
Principal investigator 1 ModernaTX, Inc. $3,490.33 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482631
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482635
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482639
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482645
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482649
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482655
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482659
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482665
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482669
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482675
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482679
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482685
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482689
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482693
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482699
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482703
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482709
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482715
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482719
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482725
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482729
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482733
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482739
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482743
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482749
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482753
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482759
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482763
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482769
Principal investigator 1 ModernaTX, Inc. $766.30 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482773
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482779
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482783
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482789
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482793
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482797
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482803
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482807
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482813
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482818
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482823
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482827
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482833
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482837
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482843
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482847
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482853
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482857
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482863
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482867
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482873
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482877
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482883
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482889
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482893
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482899
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482905
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482909
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482915
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482919
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482925
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482929
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482935
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482939
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482945
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482949
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482955
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482959
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482965
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482969
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482973
Principal investigator 1 ModernaTX, Inc. $3,490.33 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482979
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482983
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482987
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482993
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482997
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483003
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483007
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483013
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483017
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483023
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483027
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483033
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483039
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483043
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483049
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483053
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483057
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483063
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483067
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483073
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483077
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483083
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483087
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483093
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483097
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483101
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483107
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483111
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483115
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483121
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483125
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483131
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483135
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483141
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483145
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483149
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483155
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483159
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483165
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483169
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483175
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483179
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483185
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483189
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483195
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483199
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483203
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483209
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483213
Principal investigator 1 ModernaTX, Inc. $748.98 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483219
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483223
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483229
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483233
Principal investigator 1 ModernaTX, Inc. $595.08 12/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963483239
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,485.00 12/12/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125321
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,233.00 12/12/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125323
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,342.00 12/12/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125325
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,620.00 12/05/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125315
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,436.00 12/05/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125317
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,464.00 12/05/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125319
Principal investigator 1 SANOFI PASTEUR INC. $23,957.10 12/04/2022 Non-covered Recipient Entity
Research Centers Of America,llc
A Phase I, parallel, randomized, active-controlled, multi-center, dose-escalation study with early safety data reviews to assess safety and immunogenicity of a monovalent mRNA vaccine encoding influenza hemagglutinin in adults 18 years of age and older No dispute reported 06/30/2026 935558253
Principal investigator 1 Alnylam Pharmaceuticals Inc. $62,959.35 12/02/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125313
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125209
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125309
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125329
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125331
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125333
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125335
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125337
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125409
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125411
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125413
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125415
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125417
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125419
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125421
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125423
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125425
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125427
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479119
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479123
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479183
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479189
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479251
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479257
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479301
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479341
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479347
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479351
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479543
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479547
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479551
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479589
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479593
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479603
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479607
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479639
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479644
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479649
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479661
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479667
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479671
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479677
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479681
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479685
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479689
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479697
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479701
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479741
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479779
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479785
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479789
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479795
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479799
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479837
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479847
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479853
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479857
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479863
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479893
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479897
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479903
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479907
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479913
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479947
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479953
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479957
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479961
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479967
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480011
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480017
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480051
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480055
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480105
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480110
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480115
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480179
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480253
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480259
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480263
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480293
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480331
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480337
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480341
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480347
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480385
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480389
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480395
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480425
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480429
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480493
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480497
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480503
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480507
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480513
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480517
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480521
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480595
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480651
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480655
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480661
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480705
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480709
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480715
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480719
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480723
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480729
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480733
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480739
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480771
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480775
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480781
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480785
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480791
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480825
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480831
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480835
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480839
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480915
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480919
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480925
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480929
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480989
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480993
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480999
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481061
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481067
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481071
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481085
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481125
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481129
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481135
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481139
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481145
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481155
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481159
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481199
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481205
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481209
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481215
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481219
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481225
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481229
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481283
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481289
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481293
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481349
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481355
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481387
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481437
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481441
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481447
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481487
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481491
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481497
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481501
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481507
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481511
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481517
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481540
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481545
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481583
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481589
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481621
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481689
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481695
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481699
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481705
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481709
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481715
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481749
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481753
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481757
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481763
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481797
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481801
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481807
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481867
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481873
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481877
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481921
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481927
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481931
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482023
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482029
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482033
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482059
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482063
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482069
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482073
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482079
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482083
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482113
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482119
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482123
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482129
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482149
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482155
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482159
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482165
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482213
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482217
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482223
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482267
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482271
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482277
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482283
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482337
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482341
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482385
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482391
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482395
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482400
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482405
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482439
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482443
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482517
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482523
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482527
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482561
Principal investigator 1 ModernaTX, Inc. $15.39 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482567
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483419
Principal investigator 1 ModernaTX, Inc. $2,576.83 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483423
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483429
Principal investigator 1 ModernaTX, Inc. $2,230.41 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483433
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483439
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483443
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483447
Principal investigator 1 ModernaTX, Inc. $2,230.41 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483453
Principal investigator 1 ModernaTX, Inc. $322.34 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483457
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483463
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483467
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483473
Principal investigator 1 ModernaTX, Inc. $2,230.41 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483477
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483483
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483487
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483491
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483497
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483501
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483507
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483511
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483517
Principal investigator 1 ModernaTX, Inc. $322.34 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483523
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483527
Principal investigator 1 ModernaTX, Inc. $2,230.41 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483537
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483541
Principal investigator 1 ModernaTX, Inc. $322.34 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483547
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483551
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483563
Principal investigator 1 ModernaTX, Inc. $1,903.14 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483567
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483577
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483581
Principal investigator 1 ModernaTX, Inc. $377.91 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483587
Principal investigator 1 ModernaTX, Inc. $1,958.71 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483591
Principal investigator 1 ModernaTX, Inc. $1,958.71 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483597
Principal investigator 1 ModernaTX, Inc. $322.34 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483601
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483607
Principal investigator 1 ModernaTX, Inc. $322.34 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483611
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483633
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483637
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483643
Principal investigator 1 ModernaTX, Inc. $322.34 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483647
Principal investigator 1 ModernaTX, Inc. $377.91 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483651
Principal investigator 1 ModernaTX, Inc. $2,230.41 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483657
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483661
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483665
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483671
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483675
Principal investigator 1 ModernaTX, Inc. $1,958.71 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483681
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483685
Principal investigator 1 ModernaTX, Inc. $2,230.41 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483689
Principal investigator 1 ModernaTX, Inc. $2,576.83 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483695
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483699
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483705
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483709
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483715
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483719
Principal investigator 1 ModernaTX, Inc. $1,958.71 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483725
Principal investigator 1 ModernaTX, Inc. $1,958.71 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483729
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483735
Principal investigator 1 ModernaTX, Inc. $377.91 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483739
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483743
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483749
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483753
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483759
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483763
Principal investigator 1 ModernaTX, Inc. $1,958.71 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483773
Principal investigator 1 ModernaTX, Inc. $1,903.14 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483779
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483783
Principal investigator 1 ModernaTX, Inc. $1,958.71 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483789
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483793
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483799
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483803
Principal investigator 1 ModernaTX, Inc. $2,230.41 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483809
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483813
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483819
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483823
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483829
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483839
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483843
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483847
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483853
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483857
Principal investigator 1 ModernaTX, Inc. $377.91 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483867
Principal investigator 1 ModernaTX, Inc. $3,142.95 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483871
Principal investigator 1 ModernaTX, Inc. $2,576.83 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483877
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483881
Principal investigator 1 ModernaTX, Inc. $1,903.14 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483887
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483891
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483897
Principal investigator 1 ModernaTX, Inc. $322.34 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483901
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483907
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483911
Principal investigator 1 ModernaTX, Inc. $1,958.71 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483917
Principal investigator 1 ModernaTX, Inc. $2,230.41 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483921
Principal investigator 1 ModernaTX, Inc. $1,903.14 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483927
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483931
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483936
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483941
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483947
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483951
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483955
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483961
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483965
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483971
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483975
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483981
Principal investigator 1 ModernaTX, Inc. $1,903.14 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483985
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483991
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483995
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483999
Principal investigator 1 ModernaTX, Inc. $322.34 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484005
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484009
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484015
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484019
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484025
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484029
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484035
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484039
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484045
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484049
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484055
Principal investigator 1 ModernaTX, Inc. $377.91 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484059
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484065
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484069
Principal investigator 1 ModernaTX, Inc. $1,903.14 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484073
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484079
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484083
Principal investigator 1 ModernaTX, Inc. $1,903.14 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484087
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484093
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484097
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484103
Principal investigator 1 ModernaTX, Inc. $3,142.95 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484107
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484113
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484117
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484121
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484127
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484132
Principal investigator 1 ModernaTX, Inc. $1,958.71 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484137
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484143
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484147
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484153
Principal investigator 1 ModernaTX, Inc. $2,230.41 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484157
Principal investigator 1 ModernaTX, Inc. $2,230.41 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484161
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484167
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484171
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484177
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484181
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484197
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484201
Principal investigator 1 ModernaTX, Inc. $2,230.41 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484205
Principal investigator 1 ModernaTX, Inc. $377.91 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484211
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484215
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484221
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484225
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484231
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484235
Principal investigator 1 ModernaTX, Inc. $2,230.41 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484239
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484245
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484249
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484255
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484259
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484265
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484269
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484275
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484279
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484285
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484289
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484293
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484299
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484303
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484319
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484323
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484327
Principal investigator 1 ModernaTX, Inc. $2,230.41 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484333
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484337
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484343
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484347
Principal investigator 1 ModernaTX, Inc. $2,230.41 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484353
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484357
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484363
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484367
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484371
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484377
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484381
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484387
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484391
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484397
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484405
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484411
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484421
Principal investigator 1 ModernaTX, Inc. $2,230.41 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484425
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484431
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484435
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484441
Principal investigator 1 ModernaTX, Inc. $1,958.71 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484445
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484451
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484455
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484461
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484465
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484471
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484479
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484485
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484489
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484495
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484499
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484505
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484509
Principal investigator 1 ModernaTX, Inc. $377.91 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484515
Principal investigator 1 ModernaTX, Inc. $2,230.41 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484519
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484525
Principal investigator 1 ModernaTX, Inc. $1,958.71 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484529
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484535
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484539
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484543
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484549
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484559
Principal investigator 1 ModernaTX, Inc. $1,903.14 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484563
Principal investigator 1 ModernaTX, Inc. $2,230.41 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484569
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484573
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484579
Principal investigator 1 ModernaTX, Inc. $2,230.41 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484583
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484589
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484593
Principal investigator 1 ModernaTX, Inc. $322.34 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484598
Principal investigator 1 ModernaTX, Inc. $2,230.41 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484609
Principal investigator 1 ModernaTX, Inc. $1,903.14 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484613
Principal investigator 1 ModernaTX, Inc. $1,958.71 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484619
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484629
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484633
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484639
Principal investigator 1 ModernaTX, Inc. $377.91 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484645
Principal investigator 1 ModernaTX, Inc. $2,576.83 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484651
Principal investigator 1 ModernaTX, Inc. $2,230.41 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484655
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484659
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484665
Principal investigator 1 ModernaTX, Inc. $1,903.14 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484669
Principal investigator 1 ModernaTX, Inc. $1,958.71 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484675
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484679
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484695
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484699
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484705
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484709
Principal investigator 1 ModernaTX, Inc. $2,230.41 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484729
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484733
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484739
Principal investigator 1 ModernaTX, Inc. $322.34 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484743
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484753
Principal investigator 1 ModernaTX, Inc. $377.91 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484759
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484763
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484769
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484783
Principal investigator 1 ModernaTX, Inc. $1,903.14 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484803
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484823
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484861
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484881
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484907
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484927
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484947
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484981
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485001
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485019
Principal investigator 1 ModernaTX, Inc. $1,958.71 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485073
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485089
Principal investigator 1 ModernaTX, Inc. $1,903.14 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485107
Principal investigator 1 ModernaTX, Inc. $3,142.95 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485123
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485141
Principal investigator 1 ModernaTX, Inc. $322.34 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485155
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485171
Principal investigator 1 ModernaTX, Inc. $322.34 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485189
Principal investigator 1 ModernaTX, Inc. $2,230.41 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485205
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485223
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485239
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485253
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485267
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485283
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485303
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485317
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485333
Principal investigator 1 ModernaTX, Inc. $1,958.71 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485347
Principal investigator 1 ModernaTX, Inc. $1,958.71 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485361
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485381
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485405
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485421
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485435
Principal investigator 1 ModernaTX, Inc. $3,142.95 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485459
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485480
Principal investigator 1 ModernaTX, Inc. $1,958.71 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485495
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485509
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485525
Principal investigator 1 ModernaTX, Inc. $322.34 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485539
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485553
Principal investigator 1 ModernaTX, Inc. $322.34 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485567
Principal investigator 1 ModernaTX, Inc. $322.34 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485587
Principal investigator 1 ModernaTX, Inc. $322.34 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485603
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485621
Principal investigator 1 ModernaTX, Inc. $1,903.14 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485641
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485655
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485671
Principal investigator 1 ModernaTX, Inc. $1,903.14 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485685
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485701
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485709
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485730
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485739
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485755
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485769
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485783
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485797
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485811
Principal investigator 1 ModernaTX, Inc. $322.34 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485831
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485847
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485861
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485901
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485927
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485935
Principal investigator 1 ModernaTX, Inc. $2,230.41 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485951
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485965
Principal investigator 1 ModernaTX, Inc. $1,958.71 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485975
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485989
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486003
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486013
Principal investigator 1 ModernaTX, Inc. $322.34 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486027
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486053
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486067
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486077
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486087
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486091
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486097
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486102
Principal investigator 1 ModernaTX, Inc. $3,142.95 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486107
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486113
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486117
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486123
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486127
Principal investigator 1 ModernaTX, Inc. $322.34 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486133
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486153
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486157
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486161
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486167
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486171
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486177
Principal investigator 1 ModernaTX, Inc. $322.34 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486181
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486191
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486195
Principal investigator 1 ModernaTX, Inc. $2,230.41 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486201
Principal investigator 1 ModernaTX, Inc. $1,903.14 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486205
Principal investigator 1 ModernaTX, Inc. $2,230.41 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486211
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486215
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486221
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486225
Principal investigator 1 ModernaTX, Inc. $322.34 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486231
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486235
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486241
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486245
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486261
Principal investigator 1 ModernaTX, Inc. $2,230.41 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486265
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486269
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486275
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486279
Principal investigator 1 ModernaTX, Inc. $322.34 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486285
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486295
Principal investigator 1 ModernaTX, Inc. $322.34 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486299
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486305
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486309
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486313
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486319
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486323
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486329
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486335
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486345
Principal investigator 1 ModernaTX, Inc. $377.91 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486349
Principal investigator 1 ModernaTX, Inc. $2,230.41 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486355
Principal investigator 1 ModernaTX, Inc. $2,230.41 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486359
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486365
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486369
Principal investigator 1 ModernaTX, Inc. $2,230.41 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486375
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486384
Principal investigator 1 ModernaTX, Inc. $3,142.95 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486389
Principal investigator 1 ModernaTX, Inc. $2,576.83 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486395
Principal investigator 1 ModernaTX, Inc. $2,230.41 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486399
Principal investigator 1 ModernaTX, Inc. $1,903.14 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486735
Principal investigator 1 ModernaTX, Inc. $377.91 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486741
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486745
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486751
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486755
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486761
Principal investigator 1 ModernaTX, Inc. $2,230.41 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486765
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486771
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486775
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486781
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486785
Principal investigator 1 ModernaTX, Inc. $1,125.08 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486789
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486795
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486799
Principal investigator 1 ModernaTX, Inc. $2,230.41 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486805
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486809
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486815
Principal investigator 1 ModernaTX, Inc. $322.34 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486819
Principal investigator 1 ModernaTX, Inc. $1,853.74 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486825
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486831
Principal investigator 1 ModernaTX, Inc. $3,142.95 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486835
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486839
Principal investigator 1 ModernaTX, Inc. $322.34 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486845
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486849
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486855
Principal investigator 1 ModernaTX, Inc. $1,841.38 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486865
Principal investigator 1 ModernaTX, Inc. $1,958.71 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486869
Principal investigator 1 ModernaTX, Inc. $377.91 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486873
Principal investigator 1 ModernaTX, Inc. $3,142.95 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486879
Principal investigator 1 ModernaTX, Inc. $2,230.41 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486883
Principal investigator 1 ModernaTX, Inc. $2,020.46 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486887
Principal investigator 1 ModernaTX, Inc. $3,223.23 11/21/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486893
Principal investigator 1 ModernaTX, Inc. $600.00 11/18/2022 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, Randomized, Stratified, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1073 (SARS-CoV-2 and Influenza Vaccine) Compared to Co-administered mRNA-1010 (Influenza) and mRNA-1273 (SARS-CoV-2) Vaccines and to mRNA- 1010 Vaccine and mRNA-1273 Vaccine Alone in Healthy Adults 18-75 Years of Age No dispute reported 06/30/2026 963252619
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479075
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479079
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479085
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479089
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479095
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479099
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479103
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479109
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479113
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479129
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479135
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479139
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479143
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479149
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479153
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479159
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479165
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479169
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479173
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479179
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479193
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479199
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479203
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479207
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479213
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479217
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479223
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479227
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479231
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479237
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479241
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479247
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479263
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479269
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479273
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479279
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479283
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479287
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479291
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479295
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479307
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479311
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479316
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479321
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479327
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479331
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479337
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479357
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479361
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479365
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479371
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479375
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479381
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479385
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479537
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479557
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479561
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479565
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479571
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479575
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479579
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479585
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479599
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479613
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479617
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479621
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479625
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479631
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479635
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479653
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479657
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479693
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479707
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479711
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479715
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479719
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479723
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479729
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479733
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479737
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479747
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479751
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479755
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479759
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479765
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479769
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479773
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479803
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479809
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479813
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479819
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479823
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479829
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479833
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479843
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479867
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479873
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479877
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479883
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479887
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479917
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479923
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479927
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479931
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479937
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479941
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479971
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479977
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479981
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479987
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479991
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963479997
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480001
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480007
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480021
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480027
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480031
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480035
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480041
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480045
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480061
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480065
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480069
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480075
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480079
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480085
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480089
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480095
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480099
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480121
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480125
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480129
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480135
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480139
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480145
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480149
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480155
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480159
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480165
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480169
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480175
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480185
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480189
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480193
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480199
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480203
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480209
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480213
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480219
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480223
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480229
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480233
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480239
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480243
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480249
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480267
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480273
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480277
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480283
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480287
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480297
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480303
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480307
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480313
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480317
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480323
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480327
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480351
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480355
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480361
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480365
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480369
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480375
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480381
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480399
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480405
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480409
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480415
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480419
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480433
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480439
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480443
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480449
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480453
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480459
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480463
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480469
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480473
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480479
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480483
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480487
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480527
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480531
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480537
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480541
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480547
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480551
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480557
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480561
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480567
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480571
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480575
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480581
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480585
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480591
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480601
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480605
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480611
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480615
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480621
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480625
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480631
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480635
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480641
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480645
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480665
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480671
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480675
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480681
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480685
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480689
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480695
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480699
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480743
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480747
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480751
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480757
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480761
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480767
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480795
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480801
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480805
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480811
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480815
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480821
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480845
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480849
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480855
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480859
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480865
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480871
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480875
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480879
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480885
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480889
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480895
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480899
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480905
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480909
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480935
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480939
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480945
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480949
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480953
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480959
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480965
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480969
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480973
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480979
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963480983
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481003
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481007
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481013
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481017
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481023
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481027
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481033
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481037
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481043
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481047
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481053
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481057
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481077
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481081
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481091
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481095
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481101
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481105
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481109
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481115
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481119
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481149
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481165
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481169
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481175
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481179
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481185
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481189
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481195
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481235
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481239
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481245
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481249
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481253
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481259
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481263
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481269
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481275
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481279
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481299
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481303
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481309
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481319
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481325
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481329
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481335
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481339
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481345
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481359
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481365
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481369
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481373
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481379
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481383
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481393
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481397
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481403
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481407
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481411
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481417
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481421
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481427
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481431
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481451
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481457
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481462
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481467
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481473
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481477
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481481
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481521
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481527
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481531
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481535
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481549
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481555
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481559
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481565
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481569
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481575
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481579
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481593
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481599
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481603
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481609
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481613
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481617
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481627
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481631
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481637
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481641
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481647
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481651
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481657
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481661
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481667
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481671
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481677
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481681
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481685
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481719
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481723
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481727
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481733
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481739
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481743
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481767
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481771
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481777
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481781
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481787
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481791
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481811
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481817
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481821
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481827
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481831
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481837
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481841
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481845
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481851
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481855
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481859
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481863
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481883
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481887
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481893
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481897
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481903
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481907
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481913
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481917
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481937
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481941
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481945
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481951
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481957
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481961
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481965
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481971
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481975
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481981
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481985
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481991
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481995
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963481999
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482005
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482009
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482015
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482019
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482039
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482043
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482049
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482053
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482089
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482093
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482099
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482103
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482109
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482134
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482139
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482145
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482169
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482175
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482179
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482185
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482189
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482195
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482199
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482203
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482207
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482227
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482233
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482237
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482243
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482247
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482251
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482257
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482261
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482287
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482293
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482297
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482301
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482307
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482311
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482317
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482321
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482327
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482331
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482347
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482351
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482357
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482361
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482365
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482371
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482375
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482381
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482409
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482415
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482419
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482425
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482429
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482433
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482449
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482453
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482457
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482463
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482467
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482473
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482477
Principal investigator 1 ModernaTX, Inc. $3,490.33 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482483
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482487
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482493
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482497
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482503
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482507
Principal investigator 1 ModernaTX, Inc. $748.98 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482513
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482533
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482539
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482543
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482547
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482553
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482557
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482571
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482577
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482581
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482587
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482591
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482595
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482601
Principal investigator 1 ModernaTX, Inc. $15.39 11/14/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963482605
Principal investigator 1 Alnylam Pharmaceuticals Inc. $56,448.05 11/02/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125311
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 10/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125303
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125305
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125307
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 10/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125371
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 10/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125373
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 10/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125375
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 10/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125377
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125379
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125381
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125383
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125385
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125387
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125389
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125391
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125393
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125395
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125397
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125399
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125401
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125403
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125405
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910125407
Principal investigator 1 ModernaTX, Inc. $750.00 10/28/2022 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, Randomized, Stratified, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1073 (SARS-CoV-2 and Influenza Vaccine) Compared to Co-administered mRNA-1010 (Influenza) and mRNA-1273 (SARS-CoV-2) Vaccines and to mRNA- 1010 Vaccine and mRNA-1273 Vaccine Alone in Healthy Adults 18-75 Years of Age No dispute reported 06/30/2026 963252467
Principal investigator 1 ModernaTX, Inc. $6,360.00 10/28/2022 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, Randomized, Stratified, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1073 (SARS-CoV-2 and Influenza Vaccine) Compared to Co-administered mRNA-1010 (Influenza) and mRNA-1273 (SARS-CoV-2) Vaccines and to mRNA- 1010 Vaccine and mRNA-1273 Vaccine Alone in Healthy Adults 18-75 Years of Age No dispute reported 06/30/2026 963252471
Principal investigator 1 ModernaTX, Inc. $1,400.00 10/28/2022 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, Randomized, Stratified, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1073 (SARS-CoV-2 and Influenza Vaccine) Compared to Co-administered mRNA-1010 (Influenza) and mRNA-1273 (SARS-CoV-2) Vaccines and to mRNA- 1010 Vaccine and mRNA-1273 Vaccine Alone in Healthy Adults 18-75 Years of Age No dispute reported 06/30/2026 963252477
Principal investigator 1 SANOFI PASTEUR INC. $6,048.00 10/27/2022 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I, parallel, randomized, active-controlled, multi-center, dose-escalation study with early safety data reviews to assess safety and immunogenicity of a monovalent mRNA vaccine encoding influenza hemagglutinin in adults 18 years of age and older No dispute reported 06/30/2026 935555383
Principal investigator 1 SANOFI PASTEUR INC. $38,613.51 10/26/2022 Non-covered Recipient Entity
Research Centers Of America,llc
A Phase I, parallel, randomized, active-controlled, multi-center, dose-escalation study with early safety data reviews to assess safety and immunogenicity of a monovalent mRNA vaccine encoding influenza hemagglutinin in adults 18 years of age and older No dispute reported 06/30/2026 935558259
Principal investigator 1 ModernaTX, Inc. $322.34 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483413
Principal investigator 1 ModernaTX, Inc. $2,020.46 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483531
Principal investigator 1 ModernaTX, Inc. $377.91 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483557
Principal investigator 1 ModernaTX, Inc. $322.34 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483571
Principal investigator 1 ModernaTX, Inc. $322.34 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483617
Principal investigator 1 ModernaTX, Inc. $377.91 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483623
Principal investigator 1 ModernaTX, Inc. $322.34 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483627
Principal investigator 1 ModernaTX, Inc. $322.34 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483769
Principal investigator 1 ModernaTX, Inc. $322.34 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483833
Principal investigator 1 ModernaTX, Inc. $2,020.46 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963483861
Principal investigator 1 ModernaTX, Inc. $377.91 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484187
Principal investigator 1 ModernaTX, Inc. $377.91 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484191
Principal investigator 1 ModernaTX, Inc. $1,841.38 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484309
Principal investigator 1 ModernaTX, Inc. $322.34 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484313
Principal investigator 1 ModernaTX, Inc. $2,576.83 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484401
Principal investigator 1 ModernaTX, Inc. $3,223.23 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484415
Principal investigator 1 ModernaTX, Inc. $377.91 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484475
Principal investigator 1 ModernaTX, Inc. $3,223.23 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484553
Principal investigator 1 ModernaTX, Inc. $377.91 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484603
Principal investigator 1 ModernaTX, Inc. $377.91 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484623
Principal investigator 1 ModernaTX, Inc. $377.91 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484685
Principal investigator 1 ModernaTX, Inc. $322.34 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484689
Principal investigator 1 ModernaTX, Inc. $322.34 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484747
Principal investigator 1 ModernaTX, Inc. $322.34 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484775
Principal investigator 1 ModernaTX, Inc. $2,576.83 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484779
Principal investigator 1 ModernaTX, Inc. $322.34 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484843
Principal investigator 1 ModernaTX, Inc. $377.91 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484967
Principal investigator 1 ModernaTX, Inc. $377.91 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485035
Principal investigator 1 ModernaTX, Inc. $377.91 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485055
Principal investigator 1 ModernaTX, Inc. $322.34 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485451
Principal investigator 1 ModernaTX, Inc. $519.94 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485875
Principal investigator 1 ModernaTX, Inc. $322.34 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485885
Principal investigator 1 ModernaTX, Inc. $322.34 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486043
Principal investigator 1 ModernaTX, Inc. $322.34 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486083
Principal investigator 1 ModernaTX, Inc. $377.91 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486137
Principal investigator 1 ModernaTX, Inc. $322.34 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486143
Principal investigator 1 ModernaTX, Inc. $3,223.23 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486147
Principal investigator 1 ModernaTX, Inc. $2,576.83 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486187
Principal investigator 1 ModernaTX, Inc. $322.34 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486251
Principal investigator 1 ModernaTX, Inc. $3,223.23 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486255
Principal investigator 1 ModernaTX, Inc. $322.34 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486289
Principal investigator 1 ModernaTX, Inc. $1,125.08 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486339
Principal investigator 1 ModernaTX, Inc. $3,223.23 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486379
Principal investigator 1 ModernaTX, Inc. $1,125.08 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486405
Principal investigator 1 ModernaTX, Inc. $322.34 10/06/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486859
Principal investigator 1 ModernaTX, Inc. $16.00 10/05/2022 Non-covered Recipient Entity
BROWARD RESEARCH GROUP
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963291101
Principal investigator 1 ModernaTX, Inc. $80.00 10/04/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 963486897
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 09/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125109
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125111
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125113
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 09/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125135
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 09/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125137
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 09/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125139
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 09/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125141
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 09/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125143
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125145
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125147
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125149
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125151
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125153
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125155
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125157
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125159
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125161
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125163
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125165
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125167
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125169
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125171
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125173
Principal investigator 1 ModernaTX, Inc. $46.90 09/27/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486057
Principal investigator 1 ModernaTX, Inc. $189.36 09/26/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486071
Principal investigator 1 ModernaTX, Inc. $167.50 09/23/2022 Non-covered Recipient Entity
CREVE COEUR FAMILY PRACTICE
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 963292693
Principal investigator 1 SANOFI PASTEUR INC. $159,952.61 09/23/2022 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I, parallel, randomized, active-controlled, multi-center, dose-escalation study with early safety data reviews to assess safety and immunogenicity of a monovalent mRNA vaccine encoding influenza hemagglutinin in adults 18 years of age and older No dispute reported 06/30/2026 935555343
Principal investigator 1 SANOFI PASTEUR INC. $612,022.71 09/23/2022 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I, parallel, randomized, active-controlled, multi-center, dose-escalation study with early safety data reviews to assess safety and immunogenicity of a monovalent mRNA vaccine encoding influenza hemagglutinin in adults 18 years of age and older No dispute reported 06/30/2026 935555349
Principal investigator 1 ModernaTX, Inc. $169.64 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484871
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484877
Principal investigator 1 ModernaTX, Inc. $169.64 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484887
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484891
Principal investigator 1 ModernaTX, Inc. $114.91 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484897
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484901
Principal investigator 1 ModernaTX, Inc. $97.56 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484913
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484917
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484923
Principal investigator 1 ModernaTX, Inc. $165.42 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484933
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484937
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484943
Principal investigator 1 ModernaTX, Inc. $165.42 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484953
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485015
Principal investigator 1 ModernaTX, Inc. $114.91 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485025
Principal investigator 1 ModernaTX, Inc. $96.92 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485029
Principal investigator 1 ModernaTX, Inc. $114.91 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485039
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485045
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485049
Principal investigator 1 ModernaTX, Inc. $106.34 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485059
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485063
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485069
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485079
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485083
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485093
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485099
Principal investigator 1 ModernaTX, Inc. $97.56 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485103
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485199
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485209
Principal investigator 1 ModernaTX, Inc. $59.22 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485213
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485219
Principal investigator 1 ModernaTX, Inc. $59.22 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485229
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485233
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485243
Principal investigator 1 ModernaTX, Inc. $59.22 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485247
Principal investigator 1 ModernaTX, Inc. $106.34 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485257
Principal investigator 1 ModernaTX, Inc. $96.92 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485263
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485273
Principal investigator 1 ModernaTX, Inc. $96.92 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485357
Principal investigator 1 ModernaTX, Inc. $96.92 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485365
Principal investigator 1 ModernaTX, Inc. $96.92 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485371
Principal investigator 1 ModernaTX, Inc. $106.34 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485375
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485385
Principal investigator 1 ModernaTX, Inc. $106.34 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485391
Principal investigator 1 ModernaTX, Inc. $106.34 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485395
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485401
Principal investigator 1 ModernaTX, Inc. $169.64 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485411
Principal investigator 1 ModernaTX, Inc. $59.22 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485415
Principal investigator 1 ModernaTX, Inc. $59.22 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485425
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485431
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485441
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485445
Principal investigator 1 ModernaTX, Inc. $59.22 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485455
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485465
Principal investigator 1 ModernaTX, Inc. $169.64 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485469
Principal investigator 1 ModernaTX, Inc. $97.56 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485515
Principal investigator 1 ModernaTX, Inc. $169.64 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485519
Principal investigator 1 ModernaTX, Inc. $169.64 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485529
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485533
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485543
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485547
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485557
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485577
Principal investigator 1 ModernaTX, Inc. $169.64 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485583
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485593
Principal investigator 1 ModernaTX, Inc. $169.64 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485597
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485661
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485665
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485675
Principal investigator 1 ModernaTX, Inc. $59.22 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485681
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485803
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485807
Principal investigator 1 ModernaTX, Inc. $165.42 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485817
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485821
Principal investigator 1 ModernaTX, Inc. $59.22 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485827
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485837
Principal investigator 1 ModernaTX, Inc. $114.91 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485841
Principal investigator 1 ModernaTX, Inc. $59.22 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485853
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485857
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485867
Principal investigator 1 ModernaTX, Inc. $106.34 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485871
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485945
Principal investigator 1 ModernaTX, Inc. $169.64 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485955
Principal investigator 1 ModernaTX, Inc. $96.92 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485959
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485969
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486017
Principal investigator 1 ModernaTX, Inc. $114.91 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486023
Principal investigator 1 ModernaTX, Inc. $16.96 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486033
Principal investigator 1 ModernaTX, Inc. $106.34 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486037
Principal investigator 1 ModernaTX, Inc. $169.64 09/22/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486047
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484789
Principal investigator 1 ModernaTX, Inc. $3,142.95 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484793
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484799
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484809
Principal investigator 1 ModernaTX, Inc. $1,125.08 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484813
Principal investigator 1 ModernaTX, Inc. $3,223.23 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484819
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484829
Principal investigator 1 ModernaTX, Inc. $1,125.08 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484833
Principal investigator 1 ModernaTX, Inc. $2,020.46 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484837
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484847
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484851
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484857
Principal investigator 1 ModernaTX, Inc. $1,125.08 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484867
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484957
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484961
Principal investigator 1 ModernaTX, Inc. $2,020.46 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484971
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484975
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484985
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484991
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484995
Principal investigator 1 ModernaTX, Inc. $1,841.38 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485005
Principal investigator 1 ModernaTX, Inc. $1,841.38 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485011
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485113
Principal investigator 1 ModernaTX, Inc. $3,223.23 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485117
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485127
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485133
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485137
Principal investigator 1 ModernaTX, Inc. $1,125.08 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485147
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485151
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485161
Principal investigator 1 ModernaTX, Inc. $1,841.38 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485165
Principal investigator 1 ModernaTX, Inc. $3,142.95 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485175
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485179
Principal investigator 1 ModernaTX, Inc. $1,125.08 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485185
Principal investigator 1 ModernaTX, Inc. $2,183.36 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485195
Principal investigator 1 ModernaTX, Inc. $2,020.46 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485277
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485287
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485293
Principal investigator 1 ModernaTX, Inc. $1,853.74 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485297
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485307
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485313
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485323
Principal investigator 1 ModernaTX, Inc. $1,125.08 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485327
Principal investigator 1 ModernaTX, Inc. $3,223.23 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485337
Principal investigator 1 ModernaTX, Inc. $3,223.23 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485343
Principal investigator 1 ModernaTX, Inc. $2,183.36 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485353
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485475
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485485
Principal investigator 1 ModernaTX, Inc. $3,223.23 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485489
Principal investigator 1 ModernaTX, Inc. $2,183.36 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485501
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485505
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485563
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485573
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485607
Principal investigator 1 ModernaTX, Inc. $3,223.23 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485613
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485617
Principal investigator 1 ModernaTX, Inc. $3,142.95 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485627
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485631
Principal investigator 1 ModernaTX, Inc. $1,841.38 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485637
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485647
Principal investigator 1 ModernaTX, Inc. $1,841.38 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485651
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485691
Principal investigator 1 ModernaTX, Inc. $1,125.08 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485695
Principal investigator 1 ModernaTX, Inc. $3,223.23 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485705
Principal investigator 1 ModernaTX, Inc. $1,125.08 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485715
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485721
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485725
Principal investigator 1 ModernaTX, Inc. $2,020.46 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485735
Principal investigator 1 ModernaTX, Inc. $2,020.46 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485745
Principal investigator 1 ModernaTX, Inc. $1,853.74 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485749
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485759
Principal investigator 1 ModernaTX, Inc. $3,223.23 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485763
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485773
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485777
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485787
Principal investigator 1 ModernaTX, Inc. $2,183.36 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485793
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485881
Principal investigator 1 ModernaTX, Inc. $2,020.46 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485891
Principal investigator 1 ModernaTX, Inc. $3,223.23 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485895
Principal investigator 1 ModernaTX, Inc. $3,223.23 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485907
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485911
Principal investigator 1 ModernaTX, Inc. $2,020.46 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485915
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485921
Principal investigator 1 ModernaTX, Inc. $1,125.08 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485931
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485941
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485979
Principal investigator 1 ModernaTX, Inc. $322.34 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485985
Principal investigator 1 ModernaTX, Inc. $2,183.36 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485995
Principal investigator 1 ModernaTX, Inc. $1,841.38 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963485999
Principal investigator 1 ModernaTX, Inc. $1,853.74 09/19/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486009
Principal investigator 1 ModernaTX, Inc. $6,360.00 09/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, OBSERVER-BLIND, ACTIVE-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1010 CANDIDATE SEASONAL INFLUENZA VACCINE IN ADULTS 50 YEARS AND OLDER No dispute reported 06/30/2026 963486901
Principal investigator 1 SANOFI PASTEUR INC. $8,000.00 09/16/2022 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I, parallel, randomized, active-controlled, multi-center, dose-escalation study with early safety data reviews to assess safety and immunogenicity of a monovalent mRNA vaccine encoding influenza hemagglutinin in adults 18 years of age and older No dispute reported 06/30/2026 935555355
Principal investigator 1 Alnylam Pharmaceuticals Inc. $140.00 09/15/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125123
Principal investigator 1 ModernaTX, Inc. $80.00 09/08/2022 Non-covered Recipient Entity
CREVE COEUR FAMILY PRACTICE
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 963292699
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125103
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125121
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125125
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125127
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125129
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125131
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125133
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125195
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125197
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125199
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125201
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125203
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125205
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125207
Principal investigator 1 ModernaTX, Inc. $59.26 08/25/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963486063
Principal investigator 1 Alnylam Pharmaceuticals Inc. $28.35 08/23/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125105
Principal investigator 1 Alnylam Pharmaceuticals Inc. $28.00 08/23/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125107
Principal investigator 1 ModernaTX, Inc. $498.00 08/22/2022 Non-covered Recipient Entity
BROWARD RESEARCH GROUP
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963291031
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125115
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125117
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125175
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125177
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125179
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125181
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125183
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125185
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125187
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125189
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125191
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125193
Principal investigator 1 Alnylam Pharmaceuticals Inc. $37.80 07/05/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125119
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125063
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125065
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125091
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125093
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125095
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125097
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125099
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125101
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125059
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125061
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125079
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125081
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125083
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125085
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125087
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125089
Principal investigator 1 ModernaTX, Inc. $473.40 05/16/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484719
Principal investigator 1 ModernaTX, Inc. $37.83 05/13/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484715
Principal investigator 1 ModernaTX, Inc. $30.00 05/13/2022 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 963484724
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/29/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125055
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125057
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/29/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125067
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125069
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125071
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125073
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125075
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125077
Principal investigator 1 Alnylam Pharmaceuticals Inc. $198.00 04/01/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125053
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125029
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125031
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125033
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125035
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125037
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125039
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125041
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125043
Principal investigator 1 Alnylam Pharmaceuticals Inc. $176.00 03/27/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125045
Principal investigator 1 Alnylam Pharmaceuticals Inc. $132.00 03/27/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125047
Principal investigator 1 Alnylam Pharmaceuticals Inc. $176.00 03/27/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125049
Principal investigator 1 Alnylam Pharmaceuticals Inc. $70.00 03/27/2022 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910125051